Analysis Tools
immune system
|
• following DSS treatment
|
|
• in DSS treated mice production of proinflammatory cytokines is increased in the colon
|
|
• in DSS treated mice production of chemokines is increased in the colon
|
|
• mesenteric lymph nodes and spleen are heavier and enlarged 2 weeks after DSS administration is stopped indicating a prolonged inflammatory response
|
|
• unlike wild-type mice, mutant mice suffer from continued body weight loss, diarrhea, and rectal bleeding following removal of DSS from the water
• mice continue to show inflammation in the colon 2 weeks after DSS administration is stopped
• colons contain more infiltrating inflammatory cells and display more ulceration and hyperplasia during the recovery phase of DSS induced colitis but not during the early stage
• body weight of chimeric mice with wild-type hematopoietic cells eventually recovers to levels similar to wild-type mice, unlike non-chimeric mutant mice
|
homeostasis/metabolism
|
• in DSS treated mice production of proinflammatory cytokines is increased in the colon
|
|
• in DSS treated mice production of chemokines is increased in the colon
|
|
• following azoxymethane and DSS treatment mice have increase tumor burden in the colon, lose more weight, and show increased rectal bleeding
• following azoxymethane and DSS treatment mice show tumors throughout the colonic tract unlike wild-type mice where the tumors are mostly contained within the rectal and distal areas of the colon
• following azoxymethane and DSS treatment more mice develop high grade dysplasia, about 30% of which are classified as adenocarcinomas, compared to wild-type controls
• tumor burden is not increased in azoxymethane and DSS treated chimeric mice with wild-type hematopoietic cells
|
hematopoietic system
|
• following DSS treatment
|
digestive/alimentary system
|
• unlike wild-type mice, mutant mice suffer from continued body weight loss, diarrhea, and rectal bleeding following removal of DSS from the water
• mice continue to show inflammation in the colon 2 weeks after DSS administration is stopped
• colons contain more infiltrating inflammatory cells and display more ulceration and hyperplasia during the recovery phase of DSS induced colitis but not during the early stage
• body weight of chimeric mice with wild-type hematopoietic cells eventually recovers to levels similar to wild-type mice, unlike non-chimeric mutant mice
|
neoplasm
|
• following azoxymethane and DSS treatment mice have increase tumor burden in the colon, lose more weight, and show increased rectal bleeding
• following azoxymethane and DSS treatment mice show tumors throughout the colonic tract unlike wild-type mice where the tumors are mostly contained within the rectal and distal areas of the colon
• following azoxymethane and DSS treatment more mice develop high grade dysplasia, about 30% of which are classified as adenocarcinomas, compared to wild-type controls
• tumor burden is not increased in azoxymethane and DSS treated chimeric mice with wild-type hematopoietic cells
|
growth/size/body
|
• following DSS treatment
|
